Quadrant Capital Group LLC Fibrogen Inc Transaction History

Quadrant Capital Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$15.95 - $25.18 $6,667 - $10,525	418 New	418 $7,000
Q2 2022 Aug 09, 2022	SELL	$7.94 - $12.96 $103 - $168	-13 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$12.02 - $16.79 $324 - $453	-27 Reduced 67.5%	13 $0
Q4 2021 Feb 01, 2022	BUY	$9.93 - $15.39 $268 - $415	27 Added 207.69%	40 $1,000
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $132 - $346	13 New	13 $0
Q2 2020 Aug 13, 2020	SELL	$32.57 - $42.83 $325 - $428	-10 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$23.3 - $45.96 $139 - $275	6 Added 150.0%	10 $0
Q4 2019 Feb 03, 2020	SELL	$34.58 - $48.06 $6,673 - $9,275	-193 Reduced 97.97%	4 $0
Q3 2019 Oct 24, 2019	BUY	$36.98 - $48.45 $7,285 - $9,544	197 New	197 $7,000
Q2 2019 Jul 24, 2019	SELL	$35.13 - $55.53 $29,790 - $47,089	-848 Closed	0 $0
Q1 2019 Apr 29, 2019	BUY	$42.83 - $59.91 $36,319 - $50,803	848 New	848 $45,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.